{"id":37133,"date":"2018-02-21T15:13:53","date_gmt":"2018-02-21T13:13:53","guid":{"rendered":"https:\/\/blog.cofb.cat\/?p=37133"},"modified":"2018-02-21T15:13:53","modified_gmt":"2018-02-21T13:13:53","slug":"diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/","title":{"rendered":"Diabetes y enfermedad cardiovascular: m\u00e1s all\u00e1 del control de la glucemia"},"content":{"rendered":"<p>El pasado 14 de febrero se celebr\u00f3 en el COFB una jornada de <strong>revisi\u00f3n sobre el riesgo cardiovascular<\/strong> <strong>en pacientes con diabetes <\/strong>(tanto tipo I como tipo II). A lo largo de la formaci\u00f3n, tambi\u00e9n se abordaron las <strong>novedades<\/strong> que hay en torno a esta cuesti\u00f3n.<\/p>\n<p>La formaci\u00f3n, dirigida a <strong>farmac\u00e9uticos de centros de atenci\u00f3n primaria<\/strong> y de<strong> la administraci\u00f3n sanitaria, <\/strong>estuvo coordinada por <strong>Roser Vall\u00e8s, vocal de Atenci\u00f3n Primaria del COFB<\/strong>.<\/p>\n<h4><span style=\"color: #008080;\"><strong>Programa de la jornada<br \/>\n<\/strong><\/span><\/h4>\n<p>A lo largo del curso se abordaron los siguientes temas:<\/p>\n<ul>\n<li>Nuevos <strong>retos en la salud cardiovascular<\/strong> de los pacientes con diabetes<\/li>\n<li><strong>Objetivos terap\u00e9uticos<\/strong> en el paciente diab\u00e9tico<\/li>\n<li><strong>Estudios de seguridad cardiovascular<\/strong> de los antidiab\u00e9ticos nuevos: \u00bfqu\u00e9 y por qu\u00e9?<\/li>\n<li><strong>Revisi\u00f3n cr\u00edtica de los estudios <\/strong><\/li>\n<li>Nuevos <strong>mecanismos de acci\u00f3n y perspectivas de futuro<\/strong><\/li>\n<li>Estrategias de <strong>tratamiento terap\u00e9utico multifactorial<\/strong> en un paciente diab\u00e9tico. Casos cl\u00ednicos<\/li>\n<\/ul>\n<div class=\"box shadow\"><\/p>\n<h4><strong><span style=\"color: #008080;\">Cuadro docente<br \/>\n<\/span><\/strong><\/h4>\n<ul>\n<li><strong>Miguel Camafort<\/strong>, m\u00e9dico especialista senior en medicina interna del Servicio de Medicina Interna General, Unidad de Hipertensi\u00f3n y Riesgo Cardiovascular del Hospital Cl\u00ednic de Barcelona.<\/li>\n<li><strong>Xavier Cos<\/strong>, m\u00e9dico de atenci\u00f3n primaria, Director del CAP Sant Mart\u00ed de Proven\u00e7als, miembro del grupo GEDAPS de la CAMFIC, y de la RedGDPS, miembro de la <em>Primary Care Diabetes Research Network <\/em>y de la divisi\u00f3n de Endocrinolog\u00eda de la <em>Red de investigaci\u00f3n en actividades preventivas y promoci\u00f3n de la salud<\/em> (redIAPP), presidente de la Primary Care Diabetes Europe (PCDE) desde 2017.<\/li>\n<li><strong>D\u00eddaco Mauricio,<\/strong> jefe del Servicio de Endocrinolog\u00eda y Nutrici\u00f3n del Hospital Germans Trias i Pujol de Badalona, coordinador del <em>Diabetes Research Group<\/em> del Hospital Germans Trias i Pujol, miembro de la red CIBERDEM del<em>Instituto de Salud Carlos III. <\/em><\/li>\n<li><strong>Andrea Molina<\/strong>, farmac\u00e9utica, Gerencia de Armonizaci\u00f3n Farmacoterap\u00e9utica, \u00c1rea del Medicamento, Servicio Catal\u00e1n de la Salud (CatSalut).<\/li>\n<\/ul>\n<p>[caption id=&quot;attachment_37142&quot; align=&quot;aligncenter&quot; width=&quot;620&quot;]<a href=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2018\/02\/cofb.180214-08.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-37142 size-large\" title=\"De izquierda a derecha: Miguel Camafort, m\u00e9dico especialista en medicina interna; Andrea Molina, farmac\u00e9utica del \u00c1rea del Medicamento del CatSalut; Xavier Cos, m\u00e9dico de atenci\u00f3n primaria y director del CAP Sant Mart\u00ed de Proven\u00e7als; D\u00eddac Mauricio, jefe del Servicio de Endocrinolog\u00eda del Hospital Germans Trias y Pujol de Badalona y Roser Vall\u00e8s, vocal de Atenci\u00f3n Primaria del COFB.\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2018\/02\/cofb.180214-08-1024x683.jpg\" alt=\"D'esquerra a dreta: Miguel Camafort, metge especialista en medicina interna; Andrea Molina, farmac\u00e8utica de l'\u00c0rea del Medicament del CatSalut; Xavier Cos, metge d'atenci\u00f3 prim\u00e0ria i director del CAP Sant Mart\u00ed de Proven\u00e7als; D\u00eddac Mauricio, cap del Servei d'Endocrinologia de l'Hospital Germans Trias i Pujol de Badalona i Roser Vall\u00e8s, vocal d'Atenci\u00f3 Prim\u00e0ria del COFB.\" width=\"620\" height=\"414\" \/><\/a> De izquierda a derecha: Miguel Camafort, m\u00e9dico especialista en medicina interna; Andrea Molina, farmac\u00e9utica del \u00c1rea del Medicamento del CatSalut; Xavier Cos, m\u00e9dico de atenci\u00f3n primaria y director del CAP Sant Mart\u00ed de Proven\u00e7als; D\u00eddac Mauricio, jefe del Servicio de Endocrinolog\u00eda del Hospital Germans Trias i Pujol de Badalona y Roser Vall\u00e8s, vocal de Atenci\u00f3n Primaria del COFB.[\/caption]<\/p>\n<p><\/div>\n<h4><span style=\"color: #008080;\"><strong>El impacto cardiovascular de la diabetes<br \/>\n<\/strong><\/span><\/h4>\n<p>Para empezar, D\u00eddac Mauricio, jefe del servicio de Endocrinolog\u00eda del Hospital de la Santa Cruz y San Pablo, explic\u00f3 los<strong> conceptos clave para entender por qu\u00e9 es fundamental tener en cuenta el riesgo cardiovascular en pacientes con DM (<em>Diabetes Mellitus<\/em>). <\/strong>Hay que tener presente que las arterias tienen memoria y que el impacto cardiovascular de una DM de largo plazo mal controlada no es el mismo que el de una DM reci\u00e9n debutada. Adem\u00e1s, el impacto es mayor en mujeres diab\u00e9ticas que en hombres.<\/p>\n<p>A continuaci\u00f3n, el dr. <strong>Miquel Camafort<\/strong>, m\u00e9dico internista del Hospital Cl\u00ednic y <strong>Andrea Molina<\/strong>, farmac\u00e9utica del CatSalut, ofrecieron una <strong>explicaci\u00f3n de las causas del \u201cboom\u201d de estudios y ensayos sobre el riesgo cardiovascular de los \u00faltimos a\u00f1os en los f\u00e1rmacos m\u00e1s novedosos para la diabetes<\/strong>. Se trata de una exigencia de las agencias reguladoras, entre ellas el EMA, para autorizar su comercializaci\u00f3n. Consiste en <strong>estudiar el riesgo cardiovascular de los nuevos f\u00e1rmacos<\/strong>, puesto que si aumentan el riesgo, no vale la pena iniciar o continuar el tratamiento. Otro aspecto que expuso Camafort fueron los nuevos estudios en marcha y los que se publicar\u00e1n en un futuro. En los pr\u00f3ximos a\u00f1os, no entrar\u00e1n nuevos f\u00e1rmacos con mecanismos de acci\u00f3n distintos a los que existen actualmente, pero s\u00ed aparecer\u00e1n otros principios activos nuevos de los mismos grupos farmacol\u00f3gicos.<\/p>\n<figure id=\"attachment_37152\" aria-describedby=\"caption-attachment-37152\" style=\"width: 620px\" class=\"wp-caption aligncenter\"><a href=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2018\/02\/cofb.180214-05.jpg\"><img decoding=\"async\" class=\"wp-image-37152 size-large\" title=\"Didac Mauricio, durante un momento de la jornada. \" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2018\/02\/cofb.180214-05-1024x683.jpg\" alt=\"Didac Mauricio, durant un moment de la jornada. \" width=\"620\" height=\"414\" \/><\/a><figcaption id=\"caption-attachment-37152\" class=\"wp-caption-text\">D\u00eddac Mauricio, durante un momento de la jornada.<\/figcaption><\/figure>\n<h4><span style=\"color: #008080;\"><strong>Casos cl\u00ednicos para facilitar la comprensi\u00f3n del tema<\/strong><\/span><\/h4>\n<p>Para cerrar la jornada, el dr. Xavier Cots, m\u00e9dico de familia y experto en DM, conjuntamente con el dr. Camafort, expusieron dos casos cl\u00ednicos de forma interactiva, sobre c\u00f3mo tratar a pacientes diab\u00e9ticos que tienen riesgo cardiovascular elevado.<\/p>\n<p>La vocal de Atenci\u00f3n Primaria del COFB, Roser Vall\u00e8s, destac\u00f3 que <strong>la formaci\u00f3n &quot;es un tema muy actual y muy importante para el correcto tratamiento de los pacientes diab\u00e9ticos&quot;<\/strong>. Asimismo, expuso que el tema estuvo explicado &quot;de forma muy comprensible&quot;.<\/p>\n<p style=\"text-align: right;\"><strong>Con la colaboraci\u00f3n de:<\/strong><\/p>\n<p><a href=\"https:\/\/www.novonordisk.es\/\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" class=\"wp-image-37135 alignright\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2018\/02\/novo-nordisk_416x416.jpg\" alt=\"\" width=\"107\" height=\"107\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Otras publicaciones de inter\u00e9s:<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/blog.cofb.cat\/14-de-novembre-dia-mundial-de-la-diabetis-2\/\" target=\"_blank\" rel=\"noopener\">14 de noviembre, D\u00eda Mundial de la Diabetes (Noviembre 2016)<\/a><\/li>\n<li><a href=\"https:\/\/blog.cofb.cat\/diabetis-puc-fer-alguna-cosa-per-prevenir-la\/\" target=\"_blank\" rel=\"noopener\">Diabetes: \u00bfpuedo hacer algo para prevenirlo? (Noviembre 2017)<\/a><\/li>\n<li><a href=\"https:\/\/blog.cofb.cat\/mes-de-700-farmaceutics-de-barcelona-ajudaran-detectar-el-risc-de-patir-diabetis-la-campanya-atenciodiabetis\/\" target=\"_blank\" rel=\"noopener\">M\u00e1s de 700 farmac\u00e9uticos de Barcelona ayudan a detectar el riesgo de sufrir diabetes en la campa\u00f1a #Atenci\u00f3Diabetis (Noviembre 2017)<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>El pasado 14 de febrero se celebr\u00f3 en el COFB una jornada de revisi\u00f3n sobre el riesgo cardiovascular en pacientes con diabetes (tanto tipo I como tipo II). A lo largo de la formaci\u00f3n, tambi\u00e9n se abordaron las novedades que existen en torno a esta cuesti\u00f3n. La formaci\u00f3n, dirigida a [\u2026]<\/p>","protected":false},"author":1,"featured_media":37172,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[2908,197,2465,200,2198,2466,2385,2882],"class_list":["post-37133","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-diabetics","tag-diabetis","tag-diabetologia","tag-glucemia","tag-malalties-cardiovasculars","tag-pacient-diabetic","tag-prevencio-risc-cardiovascular","tag-vocalia-atencio-primaria"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"El passat 14 de febrer es va celebrar al COFB una jornada de revisi\u00f3 sobre el risc cardiovascular en pacients amb diabetis (tant tipus I com tipus II).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El passat 14 de febrer es va celebrar al COFB una jornada de revisi\u00f3 sobre el risc cardiovascular en pacients amb diabetis (tant tipus I com tipus II).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-02-21T13:13:53+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia\",\"datePublished\":\"2018-02-21T13:13:53+00:00\",\"dateModified\":\"2018-02-21T13:13:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/\"},\"wordCount\":811,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"diab\u00e8tics\",\"diabetis\",\"diabetologia\",\"gluc\u00e8mia\",\"malalties cardiovasculars\",\"pacient diab\u00e8tic\",\"prevenci\u00f3 risc cardiovascular\",\"vocalia atenci\u00f3 prim\u00e0ria\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/\",\"name\":\"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2018-02-21T13:13:53+00:00\",\"dateModified\":\"2018-02-21T13:13:53+00:00\",\"description\":\"El passat 14 de febrer es va celebrar al COFB una jornada de revisi\u00f3 sobre el risc cardiovascular en pacients amb diabetis (tant tipus I com tipus II).\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"El passat 14 de febrer es va celebrar al COFB una jornada de revisi\u00f3 sobre el risc cardiovascular en pacients amb diabetis (tant tipus I com tipus II).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/","og_locale":"es_ES","og_type":"article","og_title":"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"El passat 14 de febrer es va celebrar al COFB una jornada de revisi\u00f3 sobre el risc cardiovascular en pacients amb diabetis (tant tipus I com tipus II).","og_url":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2018-02-21T13:13:53+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"wpAdminCofbOrg","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia","datePublished":"2018-02-21T13:13:53+00:00","dateModified":"2018-02-21T13:13:53+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/"},"wordCount":811,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#primaryimage"},"thumbnailUrl":"","keywords":["diab\u00e8tics","diabetis","diabetologia","gluc\u00e8mia","malalties cardiovasculars","pacient diab\u00e8tic","prevenci\u00f3 risc cardiovascular","vocalia atenci\u00f3 prim\u00e0ria"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/","url":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/","name":"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#primaryimage"},"thumbnailUrl":"","datePublished":"2018-02-21T13:13:53+00:00","dateModified":"2018-02-21T13:13:53+00:00","description":"El passat 14 de febrer es va celebrar al COFB una jornada de revisi\u00f3 sobre el risc cardiovascular en pacients amb diabetis (tant tipus I com tipus II).","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"El passat 14 de febrer es va celebrar al COFB una jornada de revisi\u00f3 sobre el risc cardiovascular en pacients amb diabetis (tant tipus I com tipus II). Al llarg de la formaci\u00f3, tamb\u00e9 es van abordar les novetats que hi ha al voltant d&#8217;aquesta q\u00fcesti\u00f3. La formaci\u00f3, dirigida a [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/37133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=37133"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/37133\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=37133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=37133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=37133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}